Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.

Bartzokis G, Lu PH, Amar CP, Raven EP, Detore NR, Altshuler LL, Mintz J, Ventura J, Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH.

Schizophr Res. 2011 Oct;132(1):35-41. doi: 10.1016/j.schres.2011.06.029. Epub 2011 Jul 20.

2.

Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.

Bartzokis G, Lu PH, Raven EP, Amar CP, Detore NR, Couvrette AJ, Mintz J, Ventura J, Casaus LR, Luo JS, Subotnik KL, Nuechterlein KH.

Schizophr Res. 2012 Sep;140(1-3):122-8. doi: 10.1016/j.schres.2012.06.036. Epub 2012 Jul 17.

3.

Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia.

Bartzokis G, Lu PH, Nuechterlein KH, Gitlin M, Doi C, Edwards N, Lieu C, Altshuler LL, Mintz J.

Schizophr Res. 2007 Jul;93(1-3):13-22. Epub 2007 Apr 3. Erratum in: Schizophr Res. 2008 Feb;99(1-3):379.

4.

A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM.

J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.

PMID:
19906343
5.

In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia.

Bartzokis G, Lu PH, Stewart SB, Oluwadara B, Lucas AJ, Pantages J, Pratt E, Sherin JE, Altshuler LL, Mintz J, Gitlin MJ, Subotnik KL, Nuechterlein KH.

Schizophr Res. 2009 Sep;113(2-3):322-31. doi: 10.1016/j.schres.2009.06.014. Epub 2009 Jul 17.

6.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
7.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
8.

Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.

Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):101-9, 109A. doi: 10.3371/CSRP.FUBO.022213.

PMID:
23446197
9.

Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study.

De la Gándara J, San Molina L, Rubio G, Rodriguez-Morales A, Hidalgo Borrajo R, Burón JA.

Expert Rev Neurother. 2009 Oct;9(10):1463-74. doi: 10.1586/ern.09.96.

PMID:
19831836
10.

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).

Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, Lam A, Villalobos Vega JC, Cuéllar JA, de Castro FJ, Quintero CM, Martíin JF, Domínguez P, Ojeda JL, Cortés SS, Cala FI, Marín CG, Castro LM, Duaso MA, Albarracín JR, Vergara GN, Benítez AF, Cleries FM, Pérez-Brian JM, Aragón AB, Navarro JC, Biedma JA, de Pedro RB, González JF, López ME, Moreno HD, López JA, Rodríguez EO, de Hoyos CM, Sacristán MP, Martín MD, Ballesteros EM, Rodríguez PA, Menéndez LF, Rivas RS, del Pino Cuadrado P, Lauffer JC, Solano JJ, Martínez JM, Solano FG, Rodríguez PG, Rodríguez JA, Cano TR, Fortacin MD, Lobeiras JM, Sampedro JM, Bravo AP, Pellicer AF, López MD, Liste JF, Fernández MR, Losada AC, Mendez RV, Romero SA, Blanco JJ, Bonaselt IT, Mahia MC, del Valle EF, Yañez PQ, Camarasa MG, Alonso JA, Mendez GF, Feliz FD, Lamela MA, Piñero MV, Alvarado PF, Gómez IL, Martín PF, Gómez JL, López AG, Jiménez AR, Nafs AE, Barquero NC, Ortiz RF, Noguera JL, Carrasco PR, Muñoz JM, Palma MM, Hortelano CM, Bonome LS, Sevilla JS, Juan JM, Ramos JM, Muñoz JL, Guisasola JE, Vazquez LS, Guerras FC, Nebot FJ, Fernández FJ, Nicolau AL, Subirats RC, Kidias MM, Navarro VF, García BF, del Rosal FM, de Vicente Muñoz T, Ballester JA, Lieb PM, Martel AD, Bea ER, Joaquim IG, Enjuanes FB, Piñol MB, Carbonell EF, Muñoz RM, Giribets CA, Sans LA, Blanco AS, Felipe MA, Muñoz PG, Villanueva AP, Arroyo MB, Borri RC, Fallada SM, Merola MC, Rodon EP, Palmes JR, Martínez EP, Catala JM, Coca AS, Ferrandiz FP, Paya EF, Caballero GI, Bonet AF, Figueras JF, Pagador PM, Garibo MM, Camo VP, Carrillo CS, Valero CP, Rebollo FJ, García Campayo J, Sala Ayma JM, Roig MM, de Uña Mateos MA, Bertolin RG, García AM, Mazo FJ, Velasco JL, Pérez LS, Casado CJ, Barba JJ, Diaz MC, Rubio JP, Mandoli AS, Herrero AU, Martínez AR, Serrano PS, Rodríguez EN, Montesinos JS, Macia JF, Mateos Marcos AM, Soto JV, Dumont MV, Pagan JP, Martínez VB, Santiuste de Pablos M, Delgado CE, Quiles MD, López FJ, Navarro PP, Torres AM, Ingles FJ, Arias-Camison JM, Manzano JC, Peña RV, Guitarte GP, Fontecilla HB, Romero JB, Gil RS, Lozano JM, Adanez LD, Zarranz Herrera-Oria I, Jiménez JP, Vaz FC, García OS, Anton CC, Casula RR, Hernandez MC, Escabias FT, Torresano JR, Pérez-Villamil AH, Estevez L, Figuero MA, Muñoz de Morales A, Calvin JL, Criado MD, Rodríguez VM, Ambrosolio EB, Madera PM, Alfaro GP, Vidal MM, Valtuille AG, Ruiz O, Cabornero GL, Echevarria Martínez de Bujo M, Mallen MJ, Puigros JS, Martorell AL, Forteza AC, Arrebola ER, Rodríguez de la Torre M, Saiz CG, Bardolet I Casas C, Linde ER, De Arce Cordon R, Molina EM, Carazo FJ, Romero JJ, Cano DV, Dorado MS, Velazquez SC, Sánchez AJ, Leon SO, Sánchez KP, Benitez MH, Zugarramurai AI, Contreras MA, De la Varga González M, Marín PB, Robina FG, García MS, Pérez FJ, Bros PC, Gómez AC, de Dios Molina Martín J, Perera JL, Averbach MC, Perera JL, Palancares EG, Gallego de Dios MT, Rojo CF, Iglesias SS, Merino MI, Mestre NP, Urdaniz AP, Sánchez JM, Seco RG, Muñoz JF, Agut MM, Lozano ML, Herguedas FM, Pena AT, García JV, Martínez AV, Sanz Granado OS, Fernández MA, Canseco JM, López PA, Martín MA, Barrio JA, Ubago JG, Bennassar MR, Díez JM, Fleta JL, Fortes FP, López CA, Medina O, Alvarez DF, Roca JM, Valladolid GR, Tavera JA, García-Castrillon Sales JA, Llordes IB, Melgarejo CA, Cañas de la Paz F, Callol VV, García MB, García JB, Leal FJ, Corrales EC, Iglesias ES, Gómez MA, Serrano GG, Chillarón EG, Aguado FJ, Castillo JJ, González AG, Vázquez JG, Peralvarez MB, Diaz MR, Mesa MY, Artiles FJ, Chao MA, Mesa MY, del Rosario Santana P, Escudero MA, Berenguer MM, Llacer JM, Berna JA, Ortiz JB, Pardell LT, Hernández-Alvarez de Sotomayor C, Méndez MR, Garate RC, Múgica BD, González MC, Domingo JP, Navarro CS, Vera GS, Cuquerella MA, Monzo JL, Boada PC, Pérez MF, Parrado EC, Sánchez JJ, Fernández JC; e-STAR Spanish Study Group.

Eur Psychiatry. 2009 Jun;24(5):287-96. doi: 10.1016/j.eurpsy.2008.12.002. Epub 2009 Feb 4.

PMID:
19195847
11.

Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.

Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A.

J Clin Psychiatry. 2012 Sep;73(9):1224-33. doi: 10.4088/JCP.11m06905. Epub 2012 Aug 7.

PMID:
22938760
12.

Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.

Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH.

JAMA Psychiatry. 2015 Aug;72(8):822-9. doi: 10.1001/jamapsychiatry.2015.0270.

13.

Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.

Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.

Int Clin Psychopharmacol. 2013 Jul;28(4):164-70. doi: 10.1097/YIC.0b013e3283611cc3.

PMID:
23587986
14.

Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.

Arunpongpaisal S, Srisurapanont M, Kongsakon R, Kitiwattanagul K, Samanwongthai U.

J Med Assoc Thai. 2010 Mar;93(3):343-50.

PMID:
20420110
15.

Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting.

Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, Yook KH.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1231-5. doi: 10.1016/j.pnpbp.2008.03.012. Epub 2008 Mar 25.

PMID:
18442879
16.

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries.

Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L, Resseler S, Akhras K, Jacobs A.

Curr Med Res Opin. 2010 Mar;26(3):501-9. doi: 10.1185/03007990903488670.

PMID:
20014981
17.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Li H, Rui Q, Ning X, Xu H, Gu N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8. doi: 10.1016/j.pnpbp.2011.02.001. Epub 2011 Feb 18.

PMID:
21315787
18.

Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.

Taylor DM, Young CL, Mace S, Patel MX.

J Clin Psychiatry. 2004 Aug;65(8):1076-83.

PMID:
15323592
19.
20.

Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.

Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E.

Neuropsychopharmacology. 2010 Nov;35(12):2367-77. doi: 10.1038/npp.2010.111. Epub 2010 Aug 4. Erratum in: Neuropsychopharmacology. 2011 Jan;36(2):548.

Supplemental Content

Support Center